Linden Thomas Advisory Services’s Ultragenyx Pharmaceutical RARE Stock Holding History

Linden Thomas Advisory Services’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-6,172	Closed	-$285K	–	414
2023 Q2	$285K	Sell	6,172 -66	-1%	-$3.06K	0.06%	328
2023 Q1	$250K	Buy	6,238 +490	+9%	+$21K	0.06%	320
2022 Q4	$266K	Buy	+5,748	New	+$226K	0.08%	318

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Linden Thomas Advisory Services's RARE Position: Q3 2023 in Review

Linden Thomas Advisory Services sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2023, closing a stake of 6,172 shares — an estimated $285K sold.

Linden Thomas Advisory Services first reported a position in RARE in Q4 2022 and held it in 3 quarters. The position peaked at $285K in Q2 2023. 219 funds tracked by Wall St. Rank hold RARE as of Q3 2023.

Linden Thomas Advisory Services reported no remaining Ultragenyx Pharmaceutical position as of Q3 2023 after selling out during the quarter.
Linden Thomas Advisory Services sold 6,172 Ultragenyx Pharmaceutical shares in Q3 2023, an estimated $285K.
Linden Thomas Advisory Services first reported a position in Ultragenyx Pharmaceutical in Q4 2022 and held it in 3 quarters.
Linden Thomas Advisory Services's Ultragenyx Pharmaceutical position peaked at $285K in Q2 2023.
219 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2023.

Based on Linden Thomas Advisory Services's 13F filing for Q3 2023, filed 20 Oct 2023.